Innogenetics N.V. (now Fujirebio Europe N.V.) was an international

in vitro diagnostics A medical test is a medical procedure performed to detect, diagnose, or monitor diseases, disease processes, susceptibility, or to determine a course of treatment. Medical tests such as, physical and visual exams, diagnostic imaging, genetic t ...

(IVD) company, with headquarters in

Ghent Ghent ( nl, Gent ; french: Gand ; traditional English: Gaunt) is a city and a Municipalities of Belgium, municipality in the Flemish Region of Belgium. It is the capital and largest city of the East Flanders province, and the third largest i ...

, Belgium. Founded in 1985, the company developed and marketed IVD testing solutions as well as OEM raw materials. The company was acquired in September 2010 by Japanese Fujirebio Inc., an H.U. Group Holdings, Inc company, and changed name to Fujirebio Europe on October 1, 2013. The current CEO of Fujirebio Europe N.V. is Christiaan De Wilde.

History

Innogenetics was founded on 18 July 1985, by Erik Tambuyzer, Hugo Van Heuverswyn and Rudi Mariën. In 1992, the company launched the first commercial tests for

cystic fibrosis Cystic fibrosis (CF) is a rare genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. ...

Europe Europe is a large peninsula conventionally considered a continent in its own right because of its great physical size and the weight of its history and traditions. Europe is also considered a subcontinent of Eurasia and it is located enti ...

(INNO-LiPA CFTR) and in 1993 the first commercial test for

Hepatitis C virus The hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family '' Flaviviridae''. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer (hepatoc ...

(HCV)

genotyping Genotyping is the process of determining differences in the genetic make-up (genotype) of an individual by examining the individual's DNA sequence using biological assays and comparing it to another individual's sequence or a reference sequence. ...

worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer's disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer's disease research test for β-

Amyloid Amyloids are aggregates of proteins characterised by a fibrillar morphology of 7–13 nm in diameter, a beta sheet (β-sheet) secondary structure (known as cross-β) and ability to be stained by particular dyes, such as Congo red. In the hu ...

and in 2002 the first commercial test for

Hepatitis B virus ''Hepatitis B virus'' (HBV) is a partially double-stranded DNA virus, a species of the genus '' Orthohepadnavirus'' and a member of the '' Hepadnaviridae'' family of viruses. This virus causes the disease hepatitis B. Disease Despite there b ...

(HBV) genotyping (INNO-LiPA HBV Genotyping). The company was one of the first biotech companies to be listed on a European

stock exchange A stock exchange, securities exchange, or bourse is an exchange where stockbrokers and traders can buy and sell securities, such as shares of stock, bonds and other financial instruments. Stock exchanges may also provide facilities for th ...

, in 1996 it was the first biotech company listed on EASDAQ, now

NASDAQ The Nasdaq Stock Market () (National Association of Securities Dealers Automated Quotations Stock Market) is an American stock exchange based in New York City. It is the most active stock trading venue in the US by volume, and ranked second ...

Europe. Until 2008 Innogenetics had its shares traded on

Euronext Euronext N.V. (short for European New Exchange Technology) is a pan-European bourse that offers various trading and post-trade services. Traded assets include regulated equities, exchange-traded funds (ETF), warrants and certificates, bonds, ...

Brussels Brussels (french: Bruxelles or ; nl, Brussel ), officially the Brussels-Capital Region (All text and all but one graphic show the English name as Brussels-Capital Region.) (french: link=no, Région de Bruxelles-Capitale; nl, link=no, Bruss ...

. Innogenetics N.V. was acquired by Fujirebio in 2010 and changed name to Fujirebio Europe N.V. on October 1, 2013.

External links

Fujirebio website in EnglishH.U. Group website in English
{{Authority control Biotechnology companies of Belgium Pharmaceutical companies of Belgium Companies based in East Flanders